COPD 'stability' at 28 weeks predicts what happens over the next year

Design

post hoc analysis of five phase 3 randomised trials with Bayesian joint modelling

Population

patients with COPD in IMPACT and FULFIL (triple vs dual inhaled therapy) and MATINEE/METREX/METREO (mepolizumab added to triple therapy)

Primary outcome

achievement of composite stability: no moderate or severe exacerbation and no worsening in CAT score or FEV1

Effect

stability in 22% (IMPACT, week 52) and 46% (FULFIL, week 24) on triple therapy; stability at week 28 associated with 45.7% lower subsequent exacerbation risk and 51.7% lower all-cause mortality risk

A post hoc analysis across five phase 3 trials — IMPACT and FULFIL comparing triple with dual inhaled therapy, and MATINEE, METREX and METREO adding mepolizumab to triple therapy — tested a composite definition of disease stability: no moderate or severe exacerbation, and no worsening from baseline in either COPD Assessment Test score or FEV1.

Stability was reached by 22% of patients on fluticasone furoate-umeclidinium-vilanterol at week 52 in IMPACT, 46% at week 24 in FULFIL, and 18% on mepolizumab plus triple therapy at week 52. Triple therapy achieved it more often than dual, and mepolizumab more often than placebo. The prognostic finding is the useful one: patients stable at week 28 had a 45.7% lower risk of a subsequent moderate or severe exacerbation and a 51.7% lower risk of all-cause mortality after week 28 than those who were not.

COPD review consultations tend to be organised around whether anything has got worse. This offers a target that is positive and checkable with data already in the notes: no exacerbation, no CAT deterioration, no FEV1 decline. Whether treating towards stability changes outcomes is a different question — the association here is between achieving it and doing better, and patients who achieve it may simply have less aggressive disease.

• Record CAT score and FEV1 at every review so stability can actually be assessed
• Treat failure to reach stability as a prompt to review adherence, technique and therapy step, not as fixed prognosis
• The stability rates here are from trial populations on optimised therapy; real-world rates will be lower
• Mortality reduction is an association with achieving stability, not a demonstrated effect of treating towards it

Why it matters

It gives the COPD review a positive target that can be assessed from data already recorded.

Don't overread it

Post hoc analysis of trials designed for other endpoints — achieving stability marks better outcomes, it does not prove that aiming for it produces them.

The statistics, in plain English

A 51.7% lower risk of death among patients who achieved stability sounds like a treatment effect but is a prognostic association: patients whose disease stays quiet on treatment are a different group from those whose does not, and much of that difference is disease severity rather than anything the treatment did. The composite is useful as a marker; it has not been shown to be a target worth chasing.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.